Literature DB >> 8604274

High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study.

T Z Baram1, W G Mitchell, A Tournay, O C Snead, R A Hanson, E J Horton.   

Abstract

OBJECTIVE: To compare the efficacy of corticotropin (ACTH) (150 U/m2/day) and prednosone (2 mg/kg/day) given for 2 weeks, in suppressing clinical spasms and hypsarrhythmic electroencephalogram (EEG) in infantile spasms (IS). AACTH and prednisone are standard treatments for IS. ACTH at high doses causes severe dose- and duration-dependent side effects, but may be superior to prednisone, based on retrospective or uncontrolled studies. Blinded prospecive studies have shown equal efficacy of prednisone and low-dose ACTH, and low versus high-dose ACTH.
DESIGN: A prospective, randomized, single-blinded study. SUBJECTS AND METHODS: Patient population consisted of consecutive infants fulfilling entry criteria, including the presence of clinical spasms, hypsarrhythmia (or variants) during a full sleep cycle video-EEG, and no prior steroid/ACTH treatment. Response required both cessation of spasms and elimination of hypsarrhythmia by the end of the 2-week treatment period, as determined by an investigator "blinded" to treatment. Treatment of responders was tapered off over 12 days; those failing one hormone were crossed-over to the other.
RESULTS: OF 34 eligible infants, 29 were enrolled. Median age of patients was 6 months. Twenty-two infants were "symptomatic" with known or suspected cause, and seven were cryptogenic (two normal). Of 15 infants randomized to ACTH, 13 responded by EEG and clinical criteria (86.6%); Seizures stopped in an additional infant, but EEG remained hypsarrhythmic (considered a failure). Four of the 14 patients given prednisone responded (28.6%,, with complete clinical-EEG correlation), significantly less than with ACTH, (chi2 test).
CONCLUSIONS: Using a prospective, randomized approach, a 2-week course of high-dose ACTH is superior to 2 weeks of prednsone for treatment of IS, as assessed by both clinical and EEG criteria.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8604274      PMCID: PMC3100715     

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  25 in total

Review 1.  Pediatric epilepsy syndromes: an overview.

Authors:  F E Dreifuss
Journal:  Cleve Clin J Med       Date:  1989       Impact factor: 2.321

2.  Infantile myoclonic seizures: an evaluation of ACTH and corticosteroid therapy.

Authors:  J A Willoughby; D L Thurston; J Holowach
Journal:  J Pediatr       Date:  1966-12       Impact factor: 4.406

3.  Use of ACTH fragments of children with infantile spasms.

Authors:  R P Willig; I Lagenstein
Journal:  Neuropediatrics       Date:  1982-05       Impact factor: 1.947

4.  A prospective study of infantile spasms: clinical and therapeutic correlations.

Authors:  C T Lombroso
Journal:  Epilepsia       Date:  1983-04       Impact factor: 5.864

5.  Infantile spasms: some new theoretical aspects.

Authors:  R Riikonen
Journal:  Epilepsia       Date:  1983-04       Impact factor: 5.864

6.  The efficacy of corticotropin in primary infantile spasms.

Authors:  P Lerman; S Kivity
Journal:  J Pediatr       Date:  1982-08       Impact factor: 4.406

7.  Double-blind study of ACTH vs prednisone therapy in infantile spasms.

Authors:  R A Hrachovy; J D Frost; P Kellaway; T E Zion
Journal:  J Pediatr       Date:  1983-10       Impact factor: 4.406

8.  Trial of an ACTH4-9 Analogue (ORG 2766) in children with intractable seizures.

Authors:  K Pentella; D S Bachman; C A Sandman
Journal:  Neuropediatrics       Date:  1982-05       Impact factor: 1.947

9.  High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms.

Authors:  R A Hrachovy; J D Frost; D G Glaze
Journal:  J Pediatr       Date:  1994-05       Impact factor: 4.406

10.  Hypsarrhythmia: variations on the theme.

Authors:  R A Hrachovy; J D Frost; P Kellaway
Journal:  Epilepsia       Date:  1984-06       Impact factor: 5.864

View more
  84 in total

1.  How does metyrapone decrease seizures?

Authors:  C A Koch; S R Bornstein; K Pacak; G P Chrousos
Journal:  Neurosurg Rev       Date:  1998       Impact factor: 3.042

2.  Treatment of infantile spasms: the ideal and the mundane.

Authors:  Tallie Z Baram
Journal:  Epilepsia       Date:  2003-08       Impact factor: 5.864

3.  Infantile spasms: the devil is in the details, but do we see the forest for the trees?

Authors:  Barbara C Jobst
Journal:  Epilepsy Curr       Date:  2011-09       Impact factor: 7.500

Review 4.  The role of inflammation in epilepsy.

Authors:  Annamaria Vezzani; Jacqueline French; Tamas Bartfai; Tallie Z Baram
Journal:  Nat Rev Neurol       Date:  2010-12-07       Impact factor: 42.937

5.  Infantile spasms and epilepsy currents.

Authors:  Elinor Ben-Menachem
Journal:  Epilepsy Curr       Date:  2005 Jul-Aug       Impact factor: 7.500

Review 6.  Models for infantile spasms: an arduous journey to the Holy Grail...

Authors:  Tallie Z Baram
Journal:  Ann Neurol       Date:  2007-02       Impact factor: 10.422

Review 7.  A risk-benefit assessment of treatments for infantile spasms.

Authors:  R Nabbout
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 8.  West Syndrome: A Review and Guide for Paediatricians.

Authors:  Renato D'Alonzo; Donato Rigante; Elisabetta Mencaroni; Susanna Esposito
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

9.  H.p. Acthar gel and cosyntropin review: clinical and financial implications.

Authors:  Jacob Gettig; Joseph P Cummings; Karl Matuszewski
Journal:  P T       Date:  2009-05

Review 10.  Neuropeptide-mediated excitability: a key triggering mechanism for seizure generation in the developing brain.

Authors:  T Z Baram; C G Hatalski
Journal:  Trends Neurosci       Date:  1998-11       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.